Creating Hope Reauthorization Act
This bill reauthorizes a Food and Drug Administration (FDA) program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)
Specifically, the bill reauthorizes the program through FY2024, but the FDA may award a voucher afterwards in certain instances.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.